# Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Study · id `cardio:ct-nct02827708` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02827708](<https://clinicaltrials.gov/study/NCT02827708>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02827708

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

## Technical summary

Registry record NCT02827708. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2018-04-10 (actual). Results posted on 2020-02-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 324 participants (enrolled count; ClinicalTrials.gov record NCT02827708, source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)
- Started: 2016-09-20 (actual) (ClinicalTrials.gov record NCT02827708, source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)
- Primary completion: 2018-04-10 (actual) (ClinicalTrials.gov record NCT02827708, source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)
- Completion: 2018-05-15 (actual) (ClinicalTrials.gov record NCT02827708, source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)
- Results first posted: 2020-02-17 (ClinicalTrials.gov record NCT02827708, source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)
- Countries: United States; Denmark; Finland; Israel; Poland; Russia; Sweden; United Kingdom (ClinicalTrials.gov record NCT02827708, source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02827708-2020-02-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Acronym: PIONEER 5
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial (`cardio:pubmed-31189517`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fb281162a77dfc37dc52f9f31d066305a8b8cfce9ef2cdc7a1219f18d479aa19
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
